Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement firms face injunction for health claims

This article was originally published in The Tan Sheet

Executive Summary

FDA announces a permanent injunction against Brownwood Acres Foods and Cherry Capital Services, and two of their executives as a result of unapproved drug claims and unauthorized health claims about their products, which include liquid glucosamine and salmon oil capsules, agency reports Feb. 22. According to FDA, the firms and executives agreed to a consent decree that prohibits them from manufacturing and distributing products claimed to "cure, treat, mitigate or prevent diseases." Signed by a U.S. District Court in Michigan, the decree requires the firms to remove the claims from the labels of products, Web sites and brochures, and hire an expert to review claims. FDA notes firms cannot make such claims until products "are approved by the FDA as new drugs, exempt from approval as investigational new drugs, or until the claims on the products' label ... comply with the law"...

You may also be interested in...



'Peoples' Hope' Remdesivir Results Due Soon - What To Look For?

The first data readout for remdesivir, the much anticipated antiviral for the coronavirus pandemic, is expected in days. Scrip surveys antiviral development and regulatory experts to gauge their interest and the key aspects to watch for in the milestone announcement.

Coronavirus Update: FDA Fast-Tracks Blood Plasma Trials, Novavax Closes In On Vaccine Start

‘We Need Your COVID-19 Testing capacity’ UK Health Secretary Tells Life Science Firms

The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.

Topics

UsernamePublicRestriction

Register

PS101403

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel